Results 131 to 140 of about 20,614 (289)

Association between treatment with sacubitril/valsartan and the risk of Alzheimer’s disease: a clinical update

Alzheimer's Research & Therapy
Since 2014, sacubitril/valsartan (Entresto^®) is widely prescribed for heart failure. Despite neprilysin inhibition’s benefits in heart failure, concerns about potential amyloid-beta (Aβ) accumulation and Alzheimer’s disease (AD) risk have persisted ...
A. Garnier-Crussard
semanticscholar   +1 more source

Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis

Hepatology Research, EarlyView.
Sacubitril/Valsartan (Sac/Val) alleviates fibrosis and inflammation in metabolic dysfunction‐associated steatohepatitis (MASH). Its anti‐fibrotic effect is linked to the suppression of Integrin alpha 8 (Itga8), a protein crucial for hepatic stellate cell (HSC) activation and collagen production.
Hayato Kawamura, Aya Naiki‐Ito, Xiaochen Kuang, Akihiro Murakami, Masayuki Komura, Takanori Suzuki, Hiroyuki Kato, Yuko Nagayasu, Kentaro Matsuura, Kei Fujiwara, Hiromi Kataoka, Satoru Takahashi   +11 more
wiley   +1 more source

The Safety and Efficacy of the Early Use of Sacubitril/Valsartan After Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials

Cureus
Acute myocardial infarction (AMI) is a significant global cause of mortality, necessitating the exploration of innovative treatments against the condition.
Abdullah, Majid Rashid, Cuauhtemoc Jeffrey Soto, Ghazala S. Virk, Favour C Mekowulu, Sandipkumar S Chaudhari, Saima Batool, Muhammad Usama   +7 more
semanticscholar   +1 more source

Establishment of a mouse model for ischaemic heart failure induced by coronary microembolization via left ventricular oil injection

Experimental Physiology, EarlyView.
Abstract Over the past three decades, there has been a steady increase in clinical attention to ischaemic heart failure caused by coronary microembolization. Nonetheless, a suitable mouse model for studying this condition remains limited. In the present study, we developed a mouse model of coronary microembolization‐induced ischaemic heart failure by ...
Lang Pei, Yusheng Hong, Qiuyue Wu, Jianyi Lv, Changlong Li, Xueyun Huo, Xin Liu, Di Zhang, Meng Guo, Zhenwen Chen, Xiaoyan Du   +10 more
wiley   +1 more source

Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. [PDF]

, 2018
AIMS: We tested the hypothesis that candesartan improves outcomes in heart failure (HF) with mid-range ejection fraction [HFmrEF; ejection fraction (EF) 40-49%].
Borlaug, Chioncel, Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration, Fonarow, Koh, Lam, Lam, Lang, Lofman, Lupon, Mele, Meta-analysis Global Group in Chronic Heart Failure (MAGGIC), Nauta, Paulus, Pfeffer, Ponikowski, Rastogi, Rickenbacher, Sartipy, Solomon, Solomon, Solomon, Swedberg, Tsuji, Vedin, Yusuf   +25 more
core   +2 more sources

The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis

Renal Failure
Aims This study aimed to investigate the efficacy and safety of sacubitril/valsartan in abnormal renal function (eGFR < 60 ml/min/1.73m2) patients combined with heart failure based on randomized controlled trials (RCTs) and observational studies. Methods
Xinyue Yang, Jingjing Jin, Meijuan Cheng, Jinsheng Xu, Yaling Bai   +4 more
semanticscholar   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure

BMC Pharmacology and Toxicology, 2019
Background The activation of neurohumoral compensatory mechanisms is a common physiological phenomenon in heart failure in order to make up for a failing heart, which will usually have a deteriorating effect on overall health condition. Many medications,
Kawa Dizaye, Rojgar H. Ali
doaj   +1 more source

Takotsubo Cardiomyopathy Secondary to Lung Transplantation Followed by Reduced Ejection Fraction Heart Failure: A Case Report

Clinical Case Reports, Volume 14, Issue 2, February 2026.
A 23‐year‐old male with cystic fibrosis developed Takotsubo cardiomyopathy with left ventricular reduced ejection fraction during bilateral lung transplantation. One year later, he presented with reduced left ventricular ejection fraction and pulmonary edema in the context of medication non‐adherence.
Azadeh Moradkhani, Masoume Avateffazeli, Farah Naghashzadeh, Salman Soleimani, Zargham Hossein Ahmadi, Alireza Jahangiri Fard, Sina Homaee, Mohammad Varahram, Mahshid Hajiali, Shadi Shafaghi, Atefeh Abedini   +10 more
wiley   +1 more source

Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT [PDF]

, 2017
Aims: In heart failure (HF) with reduced ejection fraction and sinus rhythm, heart rate reduction with ivabradine reduces the composite incidence of cardiovascular death and HF hospitalization.
AlHabib, Boyd, Braunstein, Böhm, Böhm, Böhm, Böhm, Böhm, Böhm, Custodis, Gheorghiade, Greene, Hasenfuss, Heusch, Komajda, Lassus, Levy, Lonn, Loyaga-Rendon, Mangiacapra, Okumura, Ponikowski, Solomon, Swedberg, Tardif, Tavazzi, Tavazzi, Verbrugge, Voors   +28 more
core   +2 more sources